Evicenter
P&T meetings

Zipalertinib

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as CLN-081, TAS6417
Manufacturer
Taiho Oncology
Regulatory submission
NDA submitted February 2026
Launch
Not announced
75 sources

Section 6 of 6

References

75 sources

  1. Aggarwal and Liu (2023) (opens in a new tab)
  2. Bazhenova et al. (2021) (opens in a new tab)
  3. Behera et al. (2024) (opens in a new tab)
  4. Burnett et al. (2021) (opens in a new tab)
  5. Canada’s Drug Agency (2025) (opens in a new tab)
  6. Cao et al. (2024) (opens in a new tab)
  7. ClinicalTrials.gov NCT07128199 (opens in a new tab)
  8. Cullinan Therapeutics (opens in a new tab)
  9. Cullinan Therapeutics (2022) (opens in a new tab)
  10. Cullinan Therapeutics annual report (2026) (opens in a new tab)
  11. Cullinan Therapeutics ASCO oral presentation (2022) (opens in a new tab)
  12. Cullinan Therapeutics ASCO oral presentation (2025) (opens in a new tab)
  13. Cullinan Therapeutics ESMO poster (2025) (opens in a new tab)
  14. Cullinan Therapeutics WCLC poster (2025) (opens in a new tab)
  15. Dabbah et al. (2026) (opens in a new tab)
  16. Dempke et al. (2026) (opens in a new tab)
  17. Dixit and Das (2025) (opens in a new tab)
  18. ESMO (2024) (opens in a new tab)
  19. FDA (2018) (opens in a new tab)
  20. FDA (2024) (opens in a new tab)
  21. FDA (2025) (opens in a new tab)
  22. Hamada et al. (2024) (opens in a new tab)
  23. Hasako et al. (2018) (opens in a new tab)
  24. Health Research Authority (2025) (opens in a new tab)
  25. Heymach et al. (2025) (opens in a new tab)
  26. Horn et al. (2021) (opens in a new tab)
  27. IASLC (2026) (opens in a new tab)
  28. Jänne et al. (2025) (opens in a new tab)
  29. Journal of Clinical Oncology (2026) (opens in a new tab)
  30. Kagawa et al. (2023) (opens in a new tab)
  31. Kwon et al. (2022) (opens in a new tab)
  32. Lau et al. (2026) (opens in a new tab)
  33. Lin et al. (2022) (opens in a new tab)
  34. Lin et al. (2025) (opens in a new tab)
  35. MedKoo Biosciences (opens in a new tab)
  36. MedKoo Biosciences safety data sheet (2022) (opens in a new tab)
  37. Memorial Sloan Kettering Cancer Center (opens in a new tab)
  38. Miyamura et al. (2025) (opens in a new tab)
  39. National Cancer Institute NCI-2023-10904 (opens in a new tab)
  40. NICE TA1158 (2026) (opens in a new tab)
  41. Ou et al. (2023a) (opens in a new tab)
  42. Ou et al. (2023b) (opens in a new tab)
  43. Oxnard et al. (2013) (opens in a new tab)
  44. Park et al. (2021) (opens in a new tab)
  45. Paz-Ares et al. (2026) (opens in a new tab)
  46. Piotrowska and Yu (2026) (opens in a new tab)
  47. Piotrowska et al. (2019) (opens in a new tab)
  48. Piotrowska et al. (2021) (opens in a new tab)
  49. Piotrowska et al. (2023) (opens in a new tab)
  50. Piotrowska et al. (2023) (opens in a new tab)
  51. Piotrowska et al. (2025) (opens in a new tab)
  52. Puri et al. (2026) (opens in a new tab)
  53. Riess et al. (2018) (opens in a new tab)
  54. Taiho Oncology (opens in a new tab)
  55. Taiho Oncology (opens in a new tab)
  56. Taiho Oncology (2025) (opens in a new tab)
  57. Taiho Oncology (2025) (opens in a new tab)
  58. Taiho Oncology (2025) (opens in a new tab)
  59. Taiho Oncology (2025) (opens in a new tab)
  60. Taiho Oncology (2025) (opens in a new tab)
  61. Taiho Oncology (2026) (opens in a new tab)
  62. Taiho Oncology (2026) (opens in a new tab)
  63. Taiho Oncology (2026) (opens in a new tab)
  64. Taiho Pharmaceutical (2026) (opens in a new tab)
  65. Udagawa et al. (2019) (opens in a new tab)
  66. Udagawa et al. (2025) (opens in a new tab)
  67. Vadagam et al. (2024) (opens in a new tab)
  68. Vidal et al. (2024) (opens in a new tab)
  69. Viteri et al. (2023) (opens in a new tab)
  70. Waterhouse et al. (2026) (opens in a new tab)
  71. Xie et al. (2025) (opens in a new tab)
  72. Yang et al. (2025) (opens in a new tab)
  73. Yao et al. (2026) (opens in a new tab)
  74. Zhou et al. (2023) (opens in a new tab)
  75. Zhou et al. (2026) (opens in a new tab)